Q1 2025 · 13F-HR
GREAT POINT PARTNERS LLCholdings as filed
Filed 2025-05-15 · accession 0001172661-25-002331
$188.8M
Reported value
32
Positions
2025-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 23282W605 | CYTK | CYTOKINETICS INC | $14.9M | 7.88% | 370,000 | Common | SHARED |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $11.7M | 6.20% | 1,014,367 | Common | SHARED |
| 30052C107 | EOLS | EVOLUS INC | $11.4M | 6.02% | 944,743 | Common | SHARED |
| 00370M103 | ABVX | ABIVAX SA | $10.2M | 5.42% | 1,638,111 | Common | SHARED |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $10.1M | 5.35% | 750,000 | Common | SHARED |
| N5749R100 | 2GH | MERUS N V | $10.0M | 5.29% | 237,156 | Common | SHARED |
| 00972D105 | AKBA | AKEBIA THERAPEUTICS INC | $9.5M | 5.06% | 4,973,840 | Common | SHARED |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $8.2M | 4.36% | 245,272 | Common | SHARED |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $7.8M | 4.13% | 50,000 | Common | SHARED |
| 268158201 | DVAX | DYNAVAX TECHNOLOGIES CORP | $7.7M | 4.09% | 595,879 | Common | SHARED |
| 462222100 | IONS | IONIS PHARMACEUTICALS INC | $7.5M | 4.00% | 250,000 | Common | SHARED |
| 03237H101 | AMLX | AMYLYX PHARMACEUTICALS INC | $6.4M | 3.40% | 1,811,996 | Common | SHARED |
| 45258J102 | IMVT | IMMUNOVANT INC | $6.4M | 3.39% | 375,000 | Common | SHARED |
| 90466Y103 | — | UNICYCIVE THERAPEUTICS INC | $6.3M | 3.34% | 10,980,000 | Common | SHARED |
| 64135M105 | NGNE | NEUROGENE INC | $5.5M | 2.92% | 470,964 | Common | SHARED |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $5.0M | 2.64% | 275,000 | Common | SHARED |
| 86627T108 | SMMT | SUMMIT THERAPEUTICS INC | $4.8M | 2.55% | 250,000 | PUT | SHARED |
| 52490G102 | LEGN | LEGEND BIOTECH CORP | $4.7M | 2.48% | 138,240 | Common | SHARED |
| 92243G108 | PCVX | VAXCYTE INC | $4.4M | 2.31% | 115,517 | Common | SHARED |
| 05280R100 | AUTL | AUTOLUS THERAPEUTICS PLC | $4.2M | 2.24% | 2,728,910 | Common | SHARED |
| G4444H101 | BBOT | HELIX ACQUISITION CORP II | $4.2M | 2.24% | 373,833 | Common | SHARED |
| G9TY5A101 | ZURA | ZURA BIO LTD | $4.1M | 2.17% | 3,170,194 | Common | SHARED |
| 07373V105 | BEAM | BEAM THERAPEUTICS INC | $3.4M | 1.82% | 175,562 | Common | SHARED |
| 03940C100 | ACLXGBX | ARCELLX INC | $3.0M | 1.56% | 45,000 | Common | SHARED |
| 589492107 | MREO | MEREO BIOPHARMA GROUP PLC | $2.9M | 1.52% | 1,275,000 | Common | SHARED |
| 21077P108 | CNTX | CONTEXT THERAPEUTICS INC | $2.9M | 1.52% | 4,683,711 | Common | SHARED |
| 76200L309 | RZLT | REZOLUTE INC | $2.4M | 1.28% | 833,042 | Common | SHARED |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $2.2M | 1.14% | 149,702 | Common | SHARED |
| 92915B106 | VYGR | VOYAGER THERAPEUTICS INC | $2.1M | 1.12% | 626,275 | Common | SHARED |
| 74346M406 | PMNEUR | PROMIS NEUROSCIENCES INC | $1.8M | 0.97% | 2,645,128 | Common | SHARED |
| 91678A107 | UPB | UPSTREAM BIO INC | $1.8M | 0.97% | 300,000 | Common | SHARED |
| 729139105 | PLRX | PLIANT THERAPEUTICS INC | $1.1M | 0.61% | 850,000 | Common | SHARED |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.